Tolerability and Pharmacokinetics of Lobeglitazone, a Novel Peroxisome Proliferator-Activated Receptor-γ Agonist, After a Single Oral Administration in Healthy Female Subjects-Reference-Cited by-同舟云学术

Tolerability and Pharmacokinetics of Lobeglitazone, a Novel Peroxisome Proliferator-Activated Receptor-γ Agonist, After a Single Oral Administration in Healthy Female Subjects

Published:2014-05-07 Issue:7 Volume:34 Page:467-474
ISSN:1173-2563
Container-title:Clinical Drug Investigation
language:en
Short-container-title:Clin Drug Investig

Author:

Park Min Kyu,Kim Tae-Eun,Kim JaeWoo,Kim Chin,Yoon Seo Hyun,Cho Joo-Youn,Jang In-Jin,Yu Kyung-Sang,Lim Kyoung Soo

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s40261-014-0197-y.pdf

Reference25 articles.

1. Harold YJ, editor. Insulin resistance in type 2 diabetes. Oxford: Blackwell; 2003.

2. Scheen AJ. Hepatotoxicity with thiazolidinediones: is it a class effect? Drug Saf. 2001;24(12):873–88.

3. Kostapanos MS, Elisaf MS, Mikhailidis DP. Pioglitazone and cancer: angel or demon? Curr Pharm Des. 2013;19(27):4913–29.

4. Palee S, Chattipakorn S, Phrommintikul A, et al. PPARgamma activator, rosiglitazone: is it beneficial or harmful to the cardiovascular system? World J Cardiol. 2011;3(5):144–52.

5. FDA News Release: FDA requires removal of certain restrictions on the diabetes drug Avandia. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm376516.htm . Accessed 20 Dec 2013.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lobeglitazone and Its Therapeutic Benefits: A Review;Cureus;2023-12-06

2. Effects of Hepatic Impairment on the Pharmacokinetic Profile and Safety of Lobeglitazone;Clinical Pharmacology in Drug Development;2022-03-07

3. Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus;Diabetes & Metabolism Journal;2021-05-31

4. No Relevant Pharmacokinetic Drug–Drug Interaction Between the Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin and Lobeglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, in Healthy Subjects;Drug Design, Development and Therapy;2021-04

5. An Assessment of Pharmacokinetic Interaction Between Lobeglitazone and Sitagliptin After Multiple Oral Administrations in Healthy Men;Clinical Therapeutics;2020-06